PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+6.61%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$502M
AUM Growth
+$502M
(+33%)
Cap. Flow
+$128M
Cap. Flow
% of AUM
25.49%
Top 10 Holdings %
Top 10 Hldgs %
77.67%
Holding
30
New
5
Increased
16
Reduced
1
Closed
7
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$37.7M |
| 2 |
argenx
ARGX
|
$33.7M |
| 3 |
Incyte
INCY
|
$24.4M |
| 4 |
United Therapeutics
UTHR
|
$20.6M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$17.6M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$15.3M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$15.1M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$14.3M |
| 4 |
Zentalis Pharmaceuticals
ZNTL
|
$13.3M |
| 5 |
Prothena Corp
PRTA
|
$9.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Legend Biotech
LEGN
$6.41B
| $53.8M | 10.73% | 978,596 +146,868 | +18% | +$8.08M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $46.2M | 9.21% | 1,445,566 +478,739 | +50% | +$15.3M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $44.3M | 8.83% | 659,968 +561,585 | +571% | +$37.7M |
|
|
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $44.1M | 8.79% | 801,314 +30,000 | +4% | +$1.65M |
|
|
5
Incyte
INCY
$16.5B
| $42.2M | 8.42% | 556,043 +321,624 | +137% | +$24.4M |
|
6
Ascendis Pharma
ASND
$11.8B
| $40.2M | 8.01% | 432,170 +110,549 | +34% | +$10.3M |
|
|
7
United Therapeutics
UTHR
$13.8B
| $38.4M | 7.66% | 163,066 +87,431 | +116% | +$20.6M |
|
|
8
argenx
ARGX
$43.6B
| $33.7M | 6.71% | +88,816 | New | +$33.7M |
|
9
Immunocore
IMCR
$1.62B
| $24.9M | 4.97% | 667,417 +168,227 | +34% | +$6.28M |
|
10
Arvinas
ARVN
$568M
| $21.8M | 4.34% | 517,406 +26,073 | +5% | +$1.1M |
|
|
BCYC
11
Bicycle Therapeutics
BCYC
$511M
| $17.6M | 3.51% | +1,048,516 | New | +$17.6M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.9M | 3.36% | 876,156 +174,800 | +25% | +$3.36M |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $15.1M | 3.01% | 1,306,569 +50,518 | +4% | +$584K |
|
14
Merus
MRUS
$4.98B
| $10.2M | 2.04% | 452,244 +202,506 | +81% | +$4.58M |
|
15
Esperion Therapeutics
ESPR
$448M
| $8.96M | 1.79% | 1,408,050 +250,804 | +22% | +$1.6M |
|
16
TG Therapeutics
TGTX
$4.65B
| $8.35M | 1.66% | +1,964,709 | New | +$8.35M |
|
|
ALPN
17
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $7.04M | 1.4% | 826,779 +490,550 | +146% | +$4.17M |
|
18
Enanta Pharmaceuticals
ENTA
$180M
| $7.01M | 1.4% | +148,216 | New | +$7.01M |
|
19
Vor Biopharma
VOR
$250M
| $6.48M | 1.29% | 1,304,300 +409,896 | +46% | +$2.04M |
|
|
OYST
20
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $5.77M | 1.15% | 1,333,330 +345,632 | +35% | +$1.5M |
|
|
GRCL
21
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $4.31M | 0.86% | 783,445 | – | – |
|
22
Liquidia Corp
LQDA
$2.38B
| $3.71M | 0.74% | +850,961 | New | +$3.71M |
|
23
C4 Therapeutics
CCCC
$185M
| $552K | 0.11% | 73,149 -426,347 | -85% | -$3.22M |
|
|
24
Prothena Corp
PRTA
$441M
| – | – | -267,946 | Closed | -$9.8M |
|
|
25
Zentalis Pharmaceuticals
ZNTL
$122M
| – | – | -287,577 | Closed | -$13.3M |
|